Intercept Pharmaceuticals, Inc.
News
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week 2024 Conference
Globe Newswire MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and...\n more…
Intercept Pharmaceuticals (NASDAQ:ICPT) Earns Hold Rating from Analysts at StockNews.com
Ticker Report StockNews.com assumed coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT Free Report) in a research note released on Sunday. The firm issued a hold rating on the biopharmaceutical...\n more…
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Short Interest Update
Ticker Report Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling...\n more…
StockNews.com Begins Coverage on Intercept Pharmaceuticals (NASDAQ:ICPT)
Ticker Report StockNews.com assumed coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT Free Report) in a research note released on Friday. The firm issued a hold rating on the biopharmaceutical...\n more…
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Consensus Recommendation of "Hold" from Brokerages
Zolmax Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT Get Free Report) has received a consensus rating of Hold from the eight analysts that are currently covering the company, Marketbeat...\n more…
StockNews.com Begins Coverage on Intercept Pharmaceuticals (NASDAQ:ICPT)
Ticker Report StockNews.com initiated coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold...\n more…